{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:31:44Z","timestamp":1792024304829,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Enhancer RNAs (eRNAs), a subclass of non-coding RNAs transcribed from enhancer regions, have emerged as critical regulators of gene expression; however, their functional roles in prostate cancer remain largely unexplored. In this study, we performed integrated chromatin accessibility and transcriptomic analyses using ATAC-seq and RNA-seq on twenty pairs of prostate cancer and matched benign tissues. By incorporating chromatin immunoprecipitation sequencing data, we identified a subset of differentially expressed eRNAs significantly associated with genes involved in prostate development and oncogenic signaling pathways. Among these, lactotransferrin-eRNA (\n                    <jats:italic>LTF<\/jats:italic>\n                    e) was markedly downregulated in prostate cancer tissues, with functional analyses revealing its tumor-suppressive role. Mechanistically,\n                    <jats:italic>LTF<\/jats:italic>\n                    e promotes the transcription of its target gene, lactotransferrin (\n                    <jats:italic>LTF<\/jats:italic>\n                    ), by interacting with heterogeneous nuclear ribonucleoprotein F (HNRNPF) and facilitating enhancer-promoter chromatin interactions. Furthermore, we demonstrate that the\n                    <jats:italic>LTF<\/jats:italic>\n                    e-\n                    <jats:italic>LTF<\/jats:italic>\n                    axis facilitates ferroptosis by modulating iron transport. Notably, androgen receptor (AR) signaling disrupts\n                    <jats:italic>LTF<\/jats:italic>\n                    e-associated chromatin looping, leading to ferroptosis resistance. Therapeutically, co- administration of the AR inhibitor enzalutamide and the ferroptosis inducer RSL3 significantly suppressed tumor growth, offering a promising strategy for castration-resistant prostate cancer. Collectively, this study provides novel insights into the mechanistic role of eRNAs in prostate cancer, highlighting the\n                    <jats:italic>LTF<\/jats:italic>\n                    e-\n                    <jats:italic>LTF<\/jats:italic>\n                    axis as a critical epigenetic regulator and potential therapeutic target for improved treatment outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02170-6","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:03:30Z","timestamp":1741896210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Sheng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-9742","authenticated-orcid":false,"given":"Le","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-9334","authenticated-orcid":false,"given":"Gong-Hong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2170_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2170_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin, M. S. & Tan, H. J. The diagnosis and treatment of prostate cancer: a review. JAMA 317, 2532\u20132542 (2017).","journal-title":"JAMA"},{"key":"2170_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.eururo.2017.08.027","volume":"73","author":"S Ren","year":"2018","unstructured":"Ren, S. et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur. Urol. 73, 322\u2013339 (2018).","journal-title":"Eur. Urol."},{"key":"2170_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2021.09.025","volume":"522","author":"P Tian","year":"2021","unstructured":"Tian, P., Zhong, M. & Wei, G. H. Mechanistic insights into genetic susceptibility to prostate cancer. Cancer Lett. 522, 155\u2013163 (2021).","journal-title":"Cancer Lett."},{"key":"2170_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93\u201399 (2020).","journal-title":"Nature"},{"key":"2170_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34994-z","volume":"13","author":"N Giannareas","year":"2022","unstructured":"Giannareas, N. et al. Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG. Nat. Commun. 13, 7320 (2022).","journal-title":"Nat. Commun."},{"key":"2170_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2018.06.003","volume":"174","author":"P Gao","year":"2018","unstructured":"Gao, P. et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus. Cell 174, 576\u2013589.e18 (2018).","journal-title":"Cell"},{"key":"2170_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","volume":"2","author":"AC Watt","year":"2021","unstructured":"Watt, A. C. et al. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat. Cancer 2, 34\u201348 (2021).","journal-title":"Nat. Cancer"},{"key":"2170_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20040311","volume":"381","author":"GH Wei","year":"2004","unstructured":"Wei, G. H., Liu, D. P. & Liang, C. C. Charting gene regulatory networks: strategies, challenges and perspectives. Biochem J. 381, 1\u201312 (2004).","journal-title":"Biochem J."},{"key":"2170_CR10","doi-asserted-by":"crossref","unstructured":"Xia, J. H. & Wei, G. H. Enhancer dysfunction in 3D genome and disease. Cells 8 (2019).","DOI":"10.3390\/cells8101281"},{"key":"2170_CR11","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1016\/j.molcel.2022.10.025","volume":"82","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets. Mol. Cell 82, 4428\u20134442.e7 (2022).","journal-title":"Mol. Cell"},{"key":"2170_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","volume":"12","author":"H Ling","year":"2013","unstructured":"Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847\u2013865 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2170_CR13","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1073\/pnas.1324151111","volume":"111","author":"CL Hsieh","year":"2014","unstructured":"Hsieh, C. L. et al. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc. Natl Acad. Sci. USA 111, 7319\u20137324 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2170_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature12210","volume":"498","author":"W Li","year":"2013","unstructured":"Li, W. et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498, 516\u2013520 (2013).","journal-title":"Nature"},{"key":"2170_CR15","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1158\/0008-5472.CAN-20-4010","volume":"81","author":"S Adhikary","year":"2021","unstructured":"Adhikary, S., Roy, S., Chacon, J., Gadad, S. S. & Das, C. Implications of enhancer transcription and eRNAs in cancer. Cancer Res. 81, 4174\u20134182 (2021).","journal-title":"Cancer Res."},{"key":"2170_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nmeth.4396","volume":"14","author":"MR Corces","year":"2017","unstructured":"Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959\u2013962 (2017).","journal-title":"Nat. Methods"},{"key":"2170_CR17","doi-asserted-by":"crossref","unstructured":"Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362 (2018).","DOI":"10.1126\/science.362.6413.415-k"},{"key":"2170_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.molmet.2016.01.002","volume":"5","author":"AM Ackermann","year":"2016","unstructured":"Ackermann, A. M., Wang, Z., Schug, J., Naji, A. & Kaestner, K. H. Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes. Mol. Metab. 5, 233\u2013244 (2016).","journal-title":"Mol. Metab."},{"key":"2170_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.1630","volume":"28","author":"CY McLean","year":"2010","unstructured":"McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495\u2013501 (2010).","journal-title":"Nat. Biotechnol."},{"key":"2170_CR20","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1080\/15476286.2020.1712895","volume":"17","author":"JH Lee","year":"2020","unstructured":"Lee, J. H., Xiong, F. & Li, W. Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential. RNA Biol. 17, 1550\u20131559 (2020).","journal-title":"RNA Biol."},{"key":"2170_CR21","doi-asserted-by":"publisher","first-page":"W70","DOI":"10.1093\/nar\/gkn188","volume":"36","author":"AR Gruber","year":"2008","unstructured":"Gruber, A. R., Lorenz, R., Bernhart, S. H., Neub\u00f6ck, R. & Hofacker, I. L. The Vienna RNA websuite. Nucleic Acids Res. 36, W70\u2013W74 (2008).","journal-title":"Nucleic Acids Res."},{"key":"2170_CR22","doi-asserted-by":"publisher","first-page":"168742","DOI":"10.1016\/j.jmb.2024.168742","volume":"436","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Xiong, Y., Yang, C. & Xiao, Y. 3dRNA\/DNA: 3D structure prediction from RNA to DNA. J. Mol. Biol. 436, 168742 (2024).","journal-title":"J. Mol. Biol."},{"key":"2170_CR23","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/s41388-018-0128-0","volume":"37","author":"W Jiao","year":"2018","unstructured":"Jiao, W. et al. HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU\/p300\/EGR1\/HPSE axis. Oncogene 37, 2728\u20132745 (2018).","journal-title":"Oncogene"},{"key":"2170_CR24","doi-asserted-by":"crossref","unstructured":"Ahmed, I. et al. eRNA profiling uncovers the enhancer landscape of oesophageal adenocarcinoma and reveals new deregulated pathways. Elife 12 (2023).","DOI":"10.7554\/eLife.80840"},{"key":"2170_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrg.2016.4","volume":"17","author":"W Li","year":"2016","unstructured":"Li, W., Notani, D. & Rosenfeld, M. G. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat. Rev. Genet. 17, 207\u2013223 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"2170_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12543-5","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nat. Commun. 10, 4562 (2019).","journal-title":"Nat. Commun."},{"key":"2170_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13598-0","volume":"10","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. MyoD induced enhancer RNA interacts with hnRNPL to activate target gene transcription during myogenic differentiation. Nat. Commun. 10, 5787 (2019).","journal-title":"Nat. Commun."},{"key":"2170_CR28","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li, J. H., Liu, S., Zhou, H., Qu, L. H. & Yang, J. H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92\u2013D97 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2170_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102256","volume":"50","author":"Z Xiao","year":"2022","unstructured":"Xiao, Z. et al. Reduction of lactoferrin aggravates neuronal ferroptosis after intracerebral hemorrhagic stroke in hyperglycemic mice. Redox Biol. 50, 102256 (2022).","journal-title":"Redox Biol."},{"key":"2170_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.bbrc.2020.07.032","volume":"531","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Liu, Y., Liu, J., Kang, R. & Tang, D. NEDD4L-mediated LTF protein degradation limits ferroptosis. Biochem. Biophys. Res. Commun. 531, 581\u2013587 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2170_CR31","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.7150\/thno.52028","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer. Theranostics 11, 3167\u20133182 (2021).","journal-title":"Theranostics"},{"key":"2170_CR32","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","volume":"186","author":"D Liang","year":"2023","unstructured":"Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186, 2748\u20132764.e22 (2023).","journal-title":"Cell"},{"key":"2170_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 35, 84\u2013100.e8 (2023).","journal-title":"Cell Metab."},{"key":"2170_CR34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani, A. et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 81, 1583\u20131594 (2021).","journal-title":"Cancer Res."},{"key":"2170_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41594-020-0446-0","volume":"27","author":"V Sartorelli","year":"2020","unstructured":"Sartorelli, V. & Lauberth, S. M. Enhancer RNAs are an important regulatory layer of the epigenome. Nat. Struct. Mol. Biol. 27, 521\u2013528 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2170_CR36","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1093\/nar\/gkw1220","volume":"45","author":"S Rahman","year":"2017","unstructured":"Rahman, S. et al. Single-cell profiling reveals that eRNA accumulation at enhancer-promoter loops is not required to sustain transcription. Nucleic Acids Res. 45, 3017\u20133030 (2017).","journal-title":"Nucleic Acids Res."},{"key":"2170_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.molcel.2015.06.002","volume":"59","author":"W Li","year":"2015","unstructured":"Li, W. et al. Condensin I and II complexes license full estrogen receptor \u03b1-dependent enhancer activation. Mol. Cell 59, 188\u2013202 (2015).","journal-title":"Mol. Cell"},{"key":"2170_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27868-3","volume":"13","author":"I Chachoua","year":"2022","unstructured":"Chachoua, I. et al. Canonical WNT signaling-dependent gating of MYC requires a noncanonical CTCF function at a distal binding site. Nat. Commun. 13, 204 (2022).","journal-title":"Nat. Commun."},{"key":"2170_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"HF Yan","year":"2021","unstructured":"Yan, H. F. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct. Target Ther. 6, 49 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2170_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-024-01599-6","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang, J., Xiu, M., Wang, J., Gao, Y. & Li, Y. METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma. J. Hematol. Oncol. 17, 78 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2170_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai, K., McManus, J. M. & Sharifi, N. Hormonal therapy for prostate cancer. Endocr. Rev. 42, 354\u2013373 (2021).","journal-title":"Endocr. Rev."},{"key":"2170_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist Updat. 70, 100985 (2023).","journal-title":"Drug Resist Updat."},{"key":"2170_CR43","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res. 83, 3192\u20133204 (2023).","journal-title":"Cancer Res."},{"key":"2170_CR44","doi-asserted-by":"crossref","unstructured":"Dai, Y. H., Chen, P. H., Lee, D. J., Andrade, G. & Vallis, K. A. A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate Cancer. Eur. Urol. S0302-2838, 02608-3 (2024).","DOI":"10.1016\/j.eururo.2024.09.020"},{"key":"2170_CR45","first-page":"229","volume":"7","author":"X Ma","year":"2021","unstructured":"Ma, X., Ma, H. & Ruan, D. Evaluation of endocrine therapy combined with intensity modulated radiation therapy in patients with advanced prostate cancer. Asian Pac. J. Cancer Prev. 7, 229\u2013234 (2021).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2170_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1101\/gr.262675.120","volume":"31","author":"S Tu","year":"2021","unstructured":"Tu, S. et al. MAnorm2 for quantitatively comparing groups of ChIP-seq samples. Genome Res. 31, 131\u2013145 (2021).","journal-title":"Genome Res."},{"key":"2170_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02627-9","volume":"23","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. HyperChIP: identification of hypervariable signals across ChIP-seq or ATAC-seq samples. Genome Biol. 23, 62 (2022).","journal-title":"Genome Biol."},{"key":"2170_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2170_CR49","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"2170_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290\u2013295 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2170_CR51","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.celrep.2016.07.032","volume":"16","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y. et al. High-resolution mapping of RNA polymerases identifies mechanisms of sensitivity and resistance to BET inhibitors in t(8;21) AML. Cell Rep. 16, 2003\u20132016 (2016).","journal-title":"Cell Rep."},{"key":"2170_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"2170_CR53","doi-asserted-by":"crossref","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10 (2021).","DOI":"10.1093\/gigascience\/giab008"},{"key":"2170_CR54","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1101\/gr.136184.111","volume":"22","author":"SG Landt","year":"2012","unstructured":"Landt, S. G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 22, 1813\u20131831 (2012).","journal-title":"Genome Res."},{"key":"2170_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"2170_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"2170_CR57","doi-asserted-by":"publisher","first-page":"W361","DOI":"10.1093\/nar\/gku406","volume":"42","author":"I Paz","year":"2014","unstructured":"Paz, I., Kosti, I., Ares, M. Jr., Cline, M. & Mandel-Gutfreund, Y. RBPmap: a web server for mapping binding sites of RNA-binding proteins. Nucleic Acids Res. 42, W361\u2013W367 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2170_CR58","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"2170_CR59","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013w743 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02170-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:03:36Z","timestamp":1741896216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02170-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02170-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}